In August of this year Jeanmarie Guenot’s company Amphivena Therapeutics announced that a new drug AMV564 was approved by the FDA for use in clinical trials for acute myeloid leukemia. This Phase 1 study will evaluate the safety of the AMV dosages used in patients. The study will evaluate the anti- tumor activity of the drug and how it affect each patient.
This study will determine the maximum dosage a patient can take safely. More dosage sizes will be studied in the Phase 2 clinical trails. Amphivena Therapeutics has given patients another therapeutic option for AML and its treatment.
JeanMarie Guenot, president and chief executive officer of this Bay Area biotech startup said that the studies showed great promise for a robust therapy for patients with minimal concerns for patients safety and side effects. The studies of the drug using patient samples and animals models proved successful. She looks forward to the clinical trials with patients in the future.
AMV564 is a antibody that uses T-cells to eliminate cancer cells with CD33. CD33 is a receptor that is found on many cancer malignancies and on AML cancer cells. It showed promise in newly diagnosed and relapsed patients that were treated in the studies.
Amphivena Therapeutics. is a cancer immunotherapy company that is located in California. Its current drug AMV564 is used to treat acute myeloid leukemia. This means that the cancer progresses rapidly and if not treated in few months could be fatal. Myeloid is the type of cell that develops with this type of cancer. It is often treated with several different type of therapies.
As taken from her CrunchBase page, JeanMarie Guenot Ph.D has over 20 years experience in the industry. She has worked with many companies in research and development, business development, project and alliance management, and venture capital projects. She built and ran a company called SKS Ocular. This company developed drugs and therapies for glaucoma and macular degeneration.
At BioPharma she lead licensing, mergers, acquisitions, and commercial product portfolios. She began her career at Atlas Venture where she managed venture capital investments and started up life science companies. At the University of California she earned her Ph.D and MBA from Wharton School at the University of Pennslyvania.
Jeanmarie’s company continues innovative work in the pharmaceutical and biotechnology with developing new therapies for cancer treatment. Read some of the medical works personally published by Dr. Guenot on Pubfacts.com.